Form 4: Solenos Therapeutics Director Birgitte Volck Receives Equity Grant of Restricted Stock Units

Solenos Therapeutics director Birgitte Volck was granted 3,991 Restricted Stock Units (RSUs) on June 5, 2025, as part of her compensation, aligning her interests with shareholders.

Summary

• Birgitte Volck, a Director of SOLENO THERAPEUTICS INC (SLNO), acquired 3,991 shares of Common Stock in the form of Restricted Stock Units (RSUs) on June 5, 2025.
• The acquisition price for these RSUs was $0, indicating they were granted as compensation rather than purchased.
• Each RSU represents a contingent right to receive one share of Common Stock.
• These RSUs are subject to a vesting schedule, which will occur on the earlier of the twelve-month anniversary of June 5, 2025, or the day before the next annual stockholder meeting.
• Vesting is contingent upon Ms. Volck continuing to serve as a Service Provider through the vesting date.
• Following this transaction, Birgitte Volck beneficially owns a total of 17,536 shares of Common Stock, which includes other RSUs subject to their respective vesting schedules and conditions.

Sentiment

Score: 7

Explanation: The grant of equity to a director is generally a positive signal as it aligns management's interests with shareholders, promoting long-term value creation. It's a routine compensation event, not indicative of significant operational changes, hence a moderately positive score.

Positives

• The grant of Restricted Stock Units (RSUs) to Director Birgitte Volck aligns her financial interests directly with the long-term performance and shareholder value of Solenos Therapeutics.
• Equity compensation for directors is a standard corporate governance practice, promoting commitment and retention of key personnel.

Future Outlook

The granted Restricted Stock Units (RSUs) are set to vest on the earlier of June 5, 2026, or the day before the next annual stockholder meeting, contingent on the director's continued service.

Industry Context

The granting of Restricted Stock Units (RSUs) to directors is a common and widely accepted practice across various industries, particularly in the biotechnology and pharmaceutical sectors where long-term commitment and alignment with shareholder interests are crucial. This type of equity compensation is a standard component of director remuneration packages.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) to a director, with a vesting schedule tied to continued service, is a standard compensation mechanism widely adopted by publicly traded companies, including those in the biotechnology sector like Solenos Therapeutics.
• This practice is consistent with corporate governance best practices aimed at aligning the interests of board members with those of shareholders, similar to compensation structures seen at comparable companies such as BioMarin Pharmaceutical Inc. (BMRN) or Sarepta Therapeutics, Inc. (SRPT), which also utilize equity grants for their non-employee directors.

Corporate Governance

Related Party Transactions

• The grant of 3,991 Restricted Stock Units (RSUs) to Birgitte Volck, a Director of Solenos Therapeutics, constitutes a related party transaction as it involves compensation from the company to an insider. This is a standard and disclosed form of director remuneration.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's interests with shareholders, potentially leading to decisions that enhance long-term shareholder value.
• Employees: While not directly impacting all employees, the compensation structure for directors can set a precedent for equity-based incentives within the company.

Next Steps

• The granted RSUs will vest on the earlier of June 5, 2026, or the day before the next annual stockholder meeting, subject to continued service.

Key Dates

Keywords

Solenos Therapeutics, SLNO, Form 4, Insider Transaction, Restricted Stock Units, RSU, Director Compensation, Equity Grant, Beneficial Ownership